Bioengineering Of Cyclotides With Angiogenic Properties
Funder
National Health and Medical Research Council
Funding Amount
$488,273.00
Summary
Atherosclerosis, a gradual clogging of the arteries, is the single leading cause of death in Australia, Europe, the USA and Japan. Coronary heart disease (CHD; clogging of the coronary arteries), while secondary to atherosclerosis in most of the world, accounts for nearly 2 million deaths per year in Europe alone. In Australia CHD is the single leading cause of death. This project is aimed at developing lead molecules for the development of therapeutics capable of stimulating revascularization ( ....Atherosclerosis, a gradual clogging of the arteries, is the single leading cause of death in Australia, Europe, the USA and Japan. Coronary heart disease (CHD; clogging of the coronary arteries), while secondary to atherosclerosis in most of the world, accounts for nearly 2 million deaths per year in Europe alone. In Australia CHD is the single leading cause of death. This project is aimed at developing lead molecules for the development of therapeutics capable of stimulating revascularization (that is, opening up blocked vessels to improve blood flow) of tissues with slow or retarded circulation. Such therapeutics would improve the treatment of atherosclerosis and CHD. Peptides, small proteins, are generally not stable enough to be used as drugs. In this project we plan to engineer protein molecules based on an unusually stable family of proteins, known as the cyclotides. We will chemically synthesise analogues of cyclotides that have been altered to incorporate the activities of less stable small peptides that are able to induce therapeutic angiogenesis. Given the prevalence of CHD, the development of effective therapeutics could have a profound impact on the economic cost of the disease, which in the USA amounts to US$133.2 billion per year. This project involves collaboration between researchers from the Institute for Molecular Bioscience, who have expertise in drug design and protein chemistry, and researchers from the Centre for Research in Vascular Biology, who have expertise in vascular biology and vessel engineering. Both of these institutes are part of the University of Queensland.Read moreRead less
There is an ongoing need for the development of new anticancer drugs, particularly those directed against solid tumours. In the past plants have been an extremely valuable source of anticancer agents, including the world s best selling anticancer drug, Taxol, isolated from the Pacific Yew tree. However, such molecules are typically complex and often very expensive to manufacture or extract from natural sources. So far very little attention has been paid to protein-based molecules from plants as ....There is an ongoing need for the development of new anticancer drugs, particularly those directed against solid tumours. In the past plants have been an extremely valuable source of anticancer agents, including the world s best selling anticancer drug, Taxol, isolated from the Pacific Yew tree. However, such molecules are typically complex and often very expensive to manufacture or extract from natural sources. So far very little attention has been paid to protein-based molecules from plants as potential anticancer agents because pharmaceutical companies have focused on organic molecules. In principle protein-based molecules could be produced much more cheaply and thus made available more widely to patients than existing drugs. All that is required are the lead molecules, or proteins that display sufficient anticancer activity to be used as the basis for further optimization. We have discovered a family of plant proteins called the cyclotides that have recently been shown to have considerable promise as anticancer agents. In the current project we will use synthetic chemistry to modify selected amino acids on the surface of this new family of proteins to determine which parts of the molecules are responsible for their activity. We will use this information to design improved analogues. The project is a collaboration between researchers at the Institute for Molecular Bioscience, University of Queensland, who have expertise in the required peptide chemistry and researchers and clinicians at Uppsala University, Sweden who have a range of assays and clinical expertise to test the new molecules. Both groups have been centrally involved in the discovery of the cyclotide family of plant proteins and are committed to developing them as exciting new anticancer agents.Read moreRead less
Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Several peptides derived from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. One of these, conotoxin MVIIA, has recently been approved in the US and Europe and others, including CVID and ACVI, are in various stages of clinical investigation. These small disulfide rich peptides share the attractive features of peptid ....Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Several peptides derived from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. One of these, conotoxin MVIIA, has recently been approved in the US and Europe and others, including CVID and ACVI, are in various stages of clinical investigation. These small disulfide rich peptides share the attractive features of peptides in general of having exquisite selectivity for particular receptors, but also share the general disadvantages of peptides of short biological half-lives and poor bioavailablility. Stabilisation of these conotoxins has the potential to substantially increase their therapeutic potential. In preliminary studies we have shown that by introducing a circular petide backbone into a conotoxin using a linker sequence we can increase its stability and resistance to enzymatic degradation. We therefore propose that it will be possible to cyclise a wide range of conotoxin molecules and thereby improve their drug like properties. In this project we will use our cyclisation approach to develop new potential treatments for pain from two classes of conotoxins. One of the lead molecules shows oral bioavailability in an animal pain model and potentially represents a major breakthrough in the field of peptide drug delivery.Read moreRead less
New Peptide-based Drugs For The Treatment Of Neuropathic Pain
Funder
National Health and Medical Research Council
Funding Amount
$527,171.00
Summary
Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Peptides from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. Unfortunately, these peptides suffer from the disadvantage of short biological half-lives and poor activity when taken orally. We have developed a new approach to solve these problems that we will apply to develop new drugs for the treatment of pain.
BMP4 - A Metastasis Suppressor Gene In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$454,220.00
Summary
Breast cancer is the most common cause of cancer death in western women. Whilst the primary tumour can often be eradicated successfully, in many cases, it may have already spread to other organs, including lungs, liver and bone, causing severe morbidity. Current treatments are largely palliative and new therapies that specifically prevent to spread of breast cancer are urgently required. However, little is known about the molecular pathways regulating the spread of cancer cells. We have shown th ....Breast cancer is the most common cause of cancer death in western women. Whilst the primary tumour can often be eradicated successfully, in many cases, it may have already spread to other organs, including lungs, liver and bone, causing severe morbidity. Current treatments are largely palliative and new therapies that specifically prevent to spread of breast cancer are urgently required. However, little is known about the molecular pathways regulating the spread of cancer cells. We have shown that expression of a gene called BMP4 in tumours blocks the spread of breast cancer in a mouse model. The aim of this project is to develop the application of BMP4 as a therapy for advanced breast cancer using our mouse model. We will measure the expression of BMP4 in human breast cancer and test whether treatment with purified BMP4 protein can protect mice from the spread of breast cancer. If successful, this study will offer a new therapy for women with currently incurable breast cancer.Read moreRead less
A Study Of Muscarinic Receptors In Brain Tissue Obtained Postmortem From Subjects With Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$354,810.00
Summary
The research outlined in this proposal will examine the molecular make up of certain regions of the human brain and determine if components within those regions are altered in tissue from subjects with schizophrenia. Schizophrenia is a serious psychiatric illness that affects approximately 1% of the Australian population and the research described in this proposal seeks to help understand the cause of the illness and-or to assist in the development of new drugs with which to treat the illness. T ....The research outlined in this proposal will examine the molecular make up of certain regions of the human brain and determine if components within those regions are altered in tissue from subjects with schizophrenia. Schizophrenia is a serious psychiatric illness that affects approximately 1% of the Australian population and the research described in this proposal seeks to help understand the cause of the illness and-or to assist in the development of new drugs with which to treat the illness. The goal of the research outlined in this proposal is to determine if there are changes in specific molecules in the brain, termed muscarinic receptors. The muscarinic receptors are one way that a chemical in the brain called acetylcholine can communicate with the nerve cells in the brain. Acetylcholine is known to control important functions of the brain such as in memory, cognition and learning, all of these functions are thought to be affected in schizophrenia. Importantly, the control of all these functions involve muscarinic receptors and therefore, changes in those receptors could well produce some of the symptoms of schizophrenia. We now wish to extend our early studies which suggest there may be changes in muscarinic receptors in the brain of subjects with schizophrenia to determine which of the 5 muscarinic receptors are affected in which region of the brain by the pathology of the illness. From our existing data, we would predict that these studies will add weight to the argument that muscarinic receptors are altered in schizophrenia and provide vital information as to how drugs that target these receptors may be used to treat the illness.Read moreRead less
Deregulation Of Ribosome Signalling, Synthesis And Function During Malignant Transformation.
Funder
National Health and Medical Research Council
Funding Amount
$522,773.00
Summary
A major feature of tumour progression is accelerated cell growth and protein synthesis. Moreover, increased synthesis of ribosomes (the protein synthetic machinery) is associated with malignancy suggesting that it may play a causal role in cancer formation. In support of this, specific inhibitors of both ribosome biogenesis and function are extremely effective in inhibiting the growth of some tumours. This study will examine the mechanisms of deregulation of ribosome biogenesis and function duri ....A major feature of tumour progression is accelerated cell growth and protein synthesis. Moreover, increased synthesis of ribosomes (the protein synthetic machinery) is associated with malignancy suggesting that it may play a causal role in cancer formation. In support of this, specific inhibitors of both ribosome biogenesis and function are extremely effective in inhibiting the growth of some tumours. This study will examine the mechanisms of deregulation of ribosome biogenesis and function during cancer formation and assess for the first time whether aberrant regulation of ribosome biogenesis and function directly contributes to the initiation and-or progression of cancer.Read moreRead less
Targeting Histone Deacetylases For The Therapy Of Myc-induced Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$356,513.00
Summary
Neuroblastoma is the commonest solid tumour in early childhood. Pancreatic cancer is the fourth leading cause of cancer death in adults. In this application, we will define how proteins called histone deacetylases promote cancer initiation and progression, and whether combination therapy with an inhibitor of the histone deacetylases and another anti-cancer agent exert efficient synergistic anti-cancer effects in animal models of neuroblastoma and pancreatic cancer.
Molecular Mechanism And Novel Activators Of Amino Acid And Calcium-sensing Class 3 G-protein Coupled Receptors
Funder
National Health and Medical Research Council
Funding Amount
$519,715.00
Summary
When we eat protein-containing foods, our bodies extract twenty different amino acids for growth and tissue regeneration. Broad-spectrum amino acid sensing receptors detect the increases in blood amino acid levels and respond by triggering the release of biochemical signals. This project will establish the molecular rules by which these receptors work and identify novel activators with potential therapeutic application for the control of growth, tissue regeneration and calcium metabolism.